Abilify

ApprovedSmall molecule

KKorea Otsuka Pharmaceutical Co., Ltd.

Abilify is one of 79 small molecule programs targeting Hyperprolactinemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperprolactinemiaActive, not recruiting

SchizophreniaActive, not recruiting

Bipolar DisorderActive, not recruiting

HyperprolactinemiaApproved

Active, not recruiting

SchizophreniaApproved

Active, not recruiting

Bipolar DisorderApproved

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Abilify

KKorea Otsuka Pharmaceutical Co., Ltd.

Approved

2 2

Ozempic

Novo Nordisk

Preclinical

1 3

Resotran

Takeda

Preclinical

1 4

Lunesta

Akero Therapeutics

Preclinical

3 5

Comtan

Orion Corporation, Orion Pharma

Preclinical

1 6

Luvox

SSolvay Pharmaceuticals

Preclinical

1 7

Inversine

TTargacept Inc.

Preclinical

1 8

Permax

VValeant Pharmaceuticals

Preclinical

1 9

Pitressin

AAultman Health Foundation

Antidepressant

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizophrenia2 trials

Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 4·NCT00299702·355 enrolled

The New Strategy for Pharmacological Treatment in People With Schizophrenia

Unknown status·IInje University·Phase 4·NCT00352339·90 enrolled

Bipolar Disorder2 trials

Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness

Completed·KKorea Otsuka Pharmaceutical Co., Ltd.·Phase 4·NCT00545675·146 enrolled

Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness

Completed·KKorea Otsuka Pharmaceutical Co., Ltd.·Phase 4·NCT00545142·280 enrolled

Aripiprazole1 trial

Bioequivalence Study of Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Products), Egypt) Versus Abilify 10 mg Orodispersible Tablets (Otsuka Pharmaceutical Netherlands B.V., Netherlands)

Completed·GGenuine Research Center, Egypt·Phase 1·NCT05804721·29 enrolled

Hyperprolactinemia1 trial

Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia

Unknown status·GGenovate Biotechnology Co., Ltd.,·Phase 4·NCT00541554

Adult Subject1 trial

Bioequivalence Study of Aripiprazole in Healthy Adult Subjects Under Fasting Condition

Completed·FFuture University in Egypt·Phase 1·NCT05532254·31 enrolled

1 more indication

BOS1 trial

Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition

Unknown status·CChengdu Kanghong Pharmaceutical Group Co., Ltd.·N/A·NCT03232710·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Abilify. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Abilify compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Abilify. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Korea Otsuka Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: KKorea Otsuka Pharmaceutical Co., Ltd.

Abilify

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schizophrenia2 trials

Bipolar Disorder2 trials

Aripiprazole1 trial

Hyperprolactinemia1 trial

Adult Subject1 trial

BOS1 trial

References

Drug Info

Quick Facts

Related News